The SWOG Statistical and Data Management Center (SDMC) plays a vital role in SWOG's overall mission to direct and participate in clinical trials tht will lead to effective treatment and prevention of cancer and to improve quality of life for cancer patients and survivors. The SDMC provides statistical leadership and data management expertise in the design, implementation, monitoring, analysis and interpretation of clinical trials and translational medicine studies. Key SDMC goals include the following: a) to design and implement statistically rigorous and efficient clinical trials;b) to carefully monitor ongoing trils and use state-of-the-art statistical analysis methods to analyze and interpret study results;c) to conduct statistical methods research in clinical trial design and analysis, and the analysis of translational medicine studies;d) to develop systems and utilize technologies for high quality and timely collection, review, storage and retrieval of clinical and biologic data;e) to educate SWOG investigators and other oncology research professionals in leading edge scientific design, statistical techniques and data management methods;f) to evaluate novel strategies for the efficient collection of specific types of patient data including electronic medical record (EMR and web-based methods;and g) to be a dynamic member of the NCTN by providing a wealth of experience and leadership for NCTN endeavors such as steering committees and working groups. The SWOG SDMC contributes meaningfully to the goals of SWOG within the NCTN to provide generalizable, high quality and efficient strategies that can be used by other clinical trials organizations and researchers in the conduct of oncology clinical trials and analysis of associated biologic studies.

Public Health Relevance

Well designed and conducted clinical trials are the primary means for improving therapy for cancer, advancing the chance for cure and increasing the length and quality of life of patients. The SWOG SDMC aims to be a leader in the field through efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials have the greatest potential impact on cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180819-01
Application #
8605318
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2014-04-17
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98109
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Spurgeon, Stephen E; Till, Brian G; Martin, Peter et al. (2017) Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. J Natl Cancer Inst 109:
Janes, Holly; Brown, Marshall D; Crager, Michael R et al. (2017) Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer. Contemp Clin Trials 63:30-39
Plantinga, Anna; Zhan, Xiang; Zhao, Ni et al. (2017) MiRKAT-S: a community-level test of association between the microbiota and survival times. Microbiome 5:17
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Kerr, Kathleen F; LeBlanc, Michael; Janes, Holly (2017) Comparisons of cancer staging systems should be based on overall performance in the population. Clin Trials 14:659-660
Crew, Katherine D; Albain, Kathy S; Hershman, Dawn L et al. (2017) How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer 3:20

Showing the most recent 10 out of 132 publications